Performance in fiscal 2018
In fiscal 2018, AstraZeneca’s (AZN) revenue fell 2% YoY (year-over-year) to $22.09 billion on a CER (constant-exchange-rate) and reported basis. Its net product sales rose 4% YoY to $21.05 billion. In its fourth-quarter conference call, AstraZeneca reported that sales of new medicines Calquence, Brilinta, Fasenra, Farxiga, Lynparza, Imfinzi, and Tagrisso together rose 81% YoY in fiscal 2018.
In fiscal 2018, AstraZeneca’s oncology sales rose 50% YoY on a reported basis and 49% on a CER basis to $6.03 billion. In its fourth-quarter press release, the company attributed this performance to the robust uptake of Tagrisso, Imfinzi, and Lynparza.
Tagrisso revenue rose 95% YoY on a reported basis and 93% on a CER basis to $1.86 billion. The company expects Tagrisso to be its bestselling drug in fiscal 2019. Imfinzi sales amounted to $633 million, driven by strong US demand. The company expects the drug to benefit from international launches in future years.
AstraZeneca and Merck’s (MRK) Lynparza sales rose 118% on a reported basis and 116% on a CER basis to $647 million. According to AstraZeneca’s investor presentation, the drug has been approved in more than 60 countries, and its uptake has been robust as maintenance therapy in second-line ovarian cancer. Lynparza’s US and Japanese launch as a breast cancer indication and regulatory decisions for Lynparza’s label expansion as a breast cancer indication in Europe are expected to be key growth drivers for the drug in fiscal 2019.
In fiscal 2018, AstraZeneca’s new cardiovascular, renal, and metabolism portfolio’s sales rose 12% YoY to $4.0 billion, driven by a 30% YoY rise in Farxiga sales, 22% YoY rise in Brilinta sales, and 2% YoY rise in Bydureon sales.
In fiscal 2018, AstraZeneca’s respiratory sales rose 4% YoY to $4.91 billion. While Symbicort sales fell 9% YoY, Pulmicort sales rose 9% YoY, and Fasenra performed robustly. For more on Eli Lilly (LLY), read What Are the Key Growth Drivers for Eli Lilly in Fiscal 2019?